MX2017008013A - Formulacion congelada estable de virus de herpes simple. - Google Patents

Formulacion congelada estable de virus de herpes simple.

Info

Publication number
MX2017008013A
MX2017008013A MX2017008013A MX2017008013A MX2017008013A MX 2017008013 A MX2017008013 A MX 2017008013A MX 2017008013 A MX2017008013 A MX 2017008013A MX 2017008013 A MX2017008013 A MX 2017008013A MX 2017008013 A MX2017008013 A MX 2017008013A
Authority
MX
Mexico
Prior art keywords
herpes simplex
simplex virus
virus formulation
stable frozen
frozen
Prior art date
Application number
MX2017008013A
Other languages
English (en)
Inventor
R Litowski Jennifer
Claudia SISKA Christine
Arthur Kerwin Bruce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017008013A publication Critical patent/MX2017008013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una composición de virus vivo que se mantiene no infectiva y proporciona estabilidad mejorada del virus durante uno o más ciclos de congelado/descongelado y/o durante el almacenado a largo plazo en un estado líquido a temperaturas en el intervalo desde apenas arriba de la congelación hasta temperaturas ambiente.
MX2017008013A 2014-12-18 2015-12-15 Formulacion congelada estable de virus de herpes simple. MX2017008013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18
PCT/US2015/065858 WO2016100364A1 (en) 2014-12-18 2015-12-15 Stable frozen herpes simplex virus formulation

Publications (1)

Publication Number Publication Date
MX2017008013A true MX2017008013A (es) 2018-03-06

Family

ID=55229814

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008013A MX2017008013A (es) 2014-12-18 2015-12-15 Formulacion congelada estable de virus de herpes simple.
MX2023012564A MX2023012564A (es) 2014-12-18 2017-06-16 Formulacion congelada estable de virus de herpes simple.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012564A MX2023012564A (es) 2014-12-18 2017-06-16 Formulacion congelada estable de virus de herpes simple.

Country Status (19)

Country Link
US (2) US20170360857A1 (es)
EP (1) EP3234114B9 (es)
JP (2) JP6975041B2 (es)
KR (2) KR102549746B1 (es)
CN (1) CN107580626A (es)
AU (2) AU2015362687B2 (es)
BR (1) BR112017013009A2 (es)
CA (1) CA2971201A1 (es)
CL (1) CL2017001563A1 (es)
CO (1) CO2017007086A2 (es)
EA (1) EA201791382A1 (es)
ES (1) ES2948037T3 (es)
HK (1) HK1245823A1 (es)
IL (3) IL308119A (es)
MA (1) MA40948A (es)
MX (2) MX2017008013A (es)
SG (1) SG11201704975SA (es)
WO (1) WO2016100364A1 (es)
ZA (1) ZA201704695B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013419A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer
WO2019213509A1 (en) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
TW202039835A (zh) * 2018-12-27 2020-11-01 美商安進公司 凍乾病毒配製物
CN116209751A (zh) * 2020-07-07 2023-06-02 北京奥源和力生物技术有限公司 用于hsv-1基因编辑的指导rna及其方法
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
AU2003258060B2 (en) * 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
EP3246400B1 (en) * 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
JP6457940B2 (ja) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法

Also Published As

Publication number Publication date
HK1245823A1 (zh) 2018-08-31
CL2017001563A1 (es) 2018-01-26
SG11201704975SA (en) 2017-07-28
AU2015362687A1 (en) 2017-07-06
EP3234114B1 (en) 2023-04-12
JP2021072795A (ja) 2021-05-13
EP3234114B9 (en) 2023-06-14
JP6975041B2 (ja) 2021-12-01
JP2018502078A (ja) 2018-01-25
IL300202A (en) 2023-03-01
IL308119A (en) 2023-12-01
EA201791382A1 (ru) 2017-10-31
IL300202B1 (en) 2023-12-01
US20170360857A1 (en) 2017-12-21
CA2971201A1 (en) 2016-06-23
IL300202B2 (en) 2024-04-01
MX2023012564A (es) 2023-11-08
KR20170095270A (ko) 2017-08-22
ZA201704695B (en) 2023-12-20
EP3234114A1 (en) 2017-10-25
KR102549746B1 (ko) 2023-07-03
IL252942A0 (en) 2017-08-31
WO2016100364A1 (en) 2016-06-23
MA40948A (fr) 2017-10-25
AU2022201523A1 (en) 2022-03-24
CN107580626A (zh) 2018-01-12
US20210052680A1 (en) 2021-02-25
CO2017007086A2 (es) 2017-10-10
KR20230107375A (ko) 2023-07-14
AU2015362687B2 (en) 2021-12-09
ES2948037T3 (es) 2023-08-30
BR112017013009A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
ZA201704695B (en) Stable frozen herpes simplex virus formulation
DK3303958T3 (da) Massegodsfrysetørring ved anvendelse af sprøjtefrysning og tørring under omrøring med varme
EP3147597A4 (en) Ice storage device and refrigerator
BR112015030374A2 (pt) solução contendo trealose e dextrana para transplante de células mamíferas
WO2014186754A3 (en) Dry solid aluminum adjuvant-containing vaccines and related methods thereof
IL253389A0 (en) The composition for use in increasing the assembly efficiency of "haematopoietic" stem cells after transplantation
BR112014013428A2 (pt) combinação de um recipiente para um produto alimentar líquido e uma quantidade de propulsor e uso de um propulsor
IL249376A0 (en) Proliferation and transplantation of stem cells using notch1 and/or notch2 agonists
EP3476766C0 (en) FROZEN STORAGE CONTAINER AND SYSTEM WITH A FROZEN STORAGE CONTAINER
WO2014045202A3 (en) Cell preparation method
PL3234088T3 (pl) Ciekła kompozycja środków powierzchniowo czynnych ze szczególną kombinacją środka powierzchniowo czynnego i enzymu
BR112016022427A2 (pt) Método para preparar ovos fritos congelados
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
Янченко et al. Features of chemical composition of snow cover and precipitation in Bratsk
BR112016028662A2 (pt) composições herbicidas sólidas contendo um agente de proteção
BR112016028368A2 (pt) composições herbicidas sólidas contendo um agente de proteção
WO2019088711A3 (ko) 냉해동 안정성이 증진된 냉동생지 조성물
刘飞 et al. Effects of Finite Surface on Polarization State of Thermal Emission
Тимофеева et al. Prospects of using peat in the regional power engineering
Кулеш et al. Mathematical modeling of heat and mass transfer at peat ignition
ES1147758Y (es) Cubitera para el transporte de recipientes para bebidas, alimentos y otros objetos vinculados con la restauracion
EP3334434A4 (en) PHOSPHOLIPID COMPOSITIONS AND USE THEREOF FOR IMPROVING THE MOBILITY AND LIFENESS OF SPERMATOZOES
UA98549U (ru) Способ стабилизации потребительских свойств быстрозамороженных культивируемых грибов
TH1501005720A (th) ช็อกโกแลตน้ำแบบอ่อนนุ่มในช่วงอุณหภูมิแช่แข็ง
GB201405628D0 (en) Improvements in or relating to cold storage and diplay